那屈肝素钙与磺达肝癸钠在预防脊柱骨折患者术后深静脉血栓形成中的应用

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the application of Nadroparin Calcium and Fondaparinux Sodium in preventing deep vein thrombosis (DVT) of patients with spinal fractures.Methods Sixty patients with spinal fractures who underwent surgical treatment in our hospital from January to June 2019 were selected as the research subjects,they were divided into NC group and FS group according to the random number table method,with 30 cases in each group.The NC group was given Nadroparin Calcium early,the FS group was given Fondaparinux Sodium early,and another 35 healthy volunteers who were admitted for physical examination during the same period were selected as the control group.The incidence of DVT was compared between NC group and FS group.The three groups were compared in terms of coagulation indexes (activated partial thromboplastin time[APTT],platelet count[PLT],fibrinogen[FIB],D-dimer[D-D],antithrombin Ⅲ[AT-Ⅲ]),hemorheology indexes (low-cut viscosity of whole blood [LWBV],high-cut viscosity of whole blood [HWBV],hematocrit[HCT],[erythrocyte sedimentation rate[ESR],platelet aggregation rate[PAR]),blood flow velocity of lower extremity vein (bilateral femoral vein and popliteal vein of lower extremity).The incidence of adverse drug reactions and hospitalization time were compared between NC group and FS group.Results There was no significant difference in DVT incidence between NC group and FS group (P＞0.05).The APTT of the NC group and the FS group was shorter than that of the control group,the levels of Fib and D-D were higher than those of the control group,the AT-Ⅲlevels of the NC group were significantly lower than those of the FS group and the control group,the differences were statistically significant (P＜0.05).There was no significant difference in PLT comparison among the three groups (P＞0.05).There were no significant differences in blood flow velocity of LWBV,HWBV,HCT,ESR and PAR among the three groups (P＞0.05).There were no significant differences in the left femoral vein,right femoral vein,left iliac vein,and right iliac vein among the three groups (P＞0.05).There were no significant differences in the incidence of incision bleeding,bleeding at other sites,anemia/thrombocytopenia,nausea/vomiting,and length of hospital stay in the NC and FS groups (P＞0.05).Conclusion The preventive application of Nadroparin Calcium or Fondaparinux Sodium in patients with spinal fracture after operation can improve the coagulation index,not affect the hemorheology index of patients,not increase the incidence of DVT and adverse drug reactions of patients.The clinical use of Nadroparin Calcium or Fondaparinux Sodium should be based on the situation of patients.

Key words： Nadroparin Calcium Spinal fractures Deep vein thrombosis Prevention Fondaparinux Sodium

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	TONG Jian-ping

Cite this article:

TONG Jian-ping. Application of Nadroparin Calcium and Fondaparinux Sodium in preventing deep vein thrombosis of patients with spinal fractures[J]. 中国当代医药, 2020, 27(5): 88-91.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I5/88

[1]	杨利勇，马海港，李振，等.老年人脊柱手术后深静脉血栓的诊断与预防[J].中国组织工程研究，2017，21（23）：3694-3699.
[2]	刘剑伟，蒋卫平.髋关节置换围手术期深静脉血栓的防治[J].中国组织工程研究，2017，21（31）：4932.
[3]	尹星华，周一新，唐杞衡，等.人工髋膝关节置换术后症状性静脉血栓栓塞性疾病的危险因素分析[J].中国矫形外科杂志，2016，24（19）：1765-1769.
[4]	刘文俊，胡海燕，刘亚孔，等.脊柱手术后静脉血栓发生率的Meta分析[J].中国脊柱脊髓杂志，2017，27（10）：913-923.
[5]	常庆华.骨折患者不同应激水平对凝血功能、血小板参数及深静脉血栓形成的影响[J].当代医学，2018，24（11）：15-17.
[6]	Fisher W.Managing hip fracture and lower limb surgery in the emergency setting[J].J Trauma Acute Care Surg，2017，82（6）：1112-1121.
[7]	Janczak DT，Mimier MK，McBane RD，et al.Rivaroxaban and Apixaban for initial treatment of acute venous thromboembolism of atypical location[J].Mayo Clin Proc，2018，93（1）：40-47.
[8]	Hisatake S，Kabuki T，Kiuchi S，et al.Short-term subcutaneous fondaparinux and oral edoxaban for acute venous thromboembolism[J].Circ J，2017，81（6）：855-861.
[9]	中华医学会外科学分会血管外科学组.深静脉血栓形成的诊断和治疗指南（第三版）[J].中华普通外科杂志，2017，32（9）：807-812.
[10]	臧加成，马信龙，马剑雄，等.不同部位骨折深静脉血栓发生率的流行病学研究[J].中华骨科杂志，2016，36（9）：540-545.
[11]	干浩，李振重，韩健，等.磺达肝癸钠关键中间体异构体的合成[J].中国医药工业杂志，2016，47（10）：1229-1234.
[12]	Babin JL，Traylor KL，Witt DM.Laboratory monitoring of Low-Molecular-Weight Heparin and Fondaparinux [J].Semin Thromb Hemost，2017，43（3）：261-269.
[13]	Mastroiacovo D，Sala G，Dentali F.The safety of fondaparinux sodium for the treatment of venous thromboembolism[J].Expert Opin Drug Saf，2016，15（9）：1259-1265.
[14]	李丽莉，鄢丹，田宗梅，等.我院2013～2015年住院患者抗凝血药应用合理性分析[J].中国药房，2017，28（14）：1895-1899.
[15]	Al-Eidan FAS，Alrawkan S，Alshammary H，et al.Comparisonof argatroban and fondaparinux for the management of patients with isolated heparin-induced thrombocytopenia[J].Ann Hematol，2018，97（11）：2055-2059.
[16]	Soeiro AM，Silva PG，Roque EA，et al.Fondaparinux versus enoxaparin-which is the best anticoagulant for acute coronary syndrome?-Brazilian registry data[J].Arq Bras Cardiol，2016，107（3）：239-244.